Actinogen Medical Overview

  • Founded
  • 1999

Founded
  • Status
  • Public

  • Stock Symbol
  • ACW

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $0.07

  • (As of Monday Closing)

Actinogen Medical General Information

Description

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Stock Exchange
ASX
Primary Office
  • Level 9, 109 Pitt Street
  • Suite 901
  • Sydney, New South Wales 2000
  • Australia
+61 (02) 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Actinogen Medical Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.07 $0.08 $0.03 - $0.13 $135M 1.8B 1.97M

Actinogen Medical Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 30-Jun-2022 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020
EV 92,889 50,614 152,287 13,678
EBITDA (6,608) (2,634) (3,338)
Net Income (6,882) (2,919) (3,570)
Total Assets 16,033 13,808 8,202
Total Debt 114 178 268
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Actinogen Medical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Actinogen Medical‘s full profile, request access.

Request a free trial

Actinogen Medical Patents

Actinogen Medical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022902939-A0 Identification of subjects for 11b-hsd1 inhibitor treatment Pending 07-Oct-2022
AU-2022901596-A0 Treatment or antidepressant resistant subjects Pending 10-Jun-2022
AU-2020904060-A0 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof Pending 06-Nov-2020
AU-2020359291-A1 Medicinal cognitive treatments Pending 30-Sep-2019 0000000000
CA-3152902-A1 Medicinal cognitive treatments Pending 30-Sep-2019 A61K31/497
To view Actinogen Medical’s complete patent history, request access »

Actinogen Medical Executive Team (6)

Name Title Board Seat Contact Info
Steven Gourlay Ph.D Chief Executive Officer & Managing Director
Jeff Carter Chief Financial Officer
Michael Roberts Executive, Investor Relations
Christian Toouli Ph.D Head, Business Development
Paul Rolan MD Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Actinogen Medical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Actinogen Medical‘s full profile, request access.

Request a free trial

Actinogen Medical Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 01-Dec-2014 0000000000 00.000 Drug Discovery
Celgenics 17-Oct-2011 Merger/Acquisition 00000 Biotechnology
To view Actinogen Medical’s complete acquisitions history, request access »